Table 1.
Demographic, Treatment, and CNS Collection Data Relating to the CNS Tissue Studied
| Sex | Age | PMI | Suicide | DOI | FRADD | ||
|---|---|---|---|---|---|---|---|
| Diagnoses | (M/F) | (y) | (hr) | CNS pH | Y / N | (y) | (Cpz) |
| Controls | 16/4 | 47 ± 3.6 | 43 ± 3.6 | 6.40 ± 0.04 | |||
| Schizophrenia | 31/9 | 48 ± 2.6 | 42 ± 2.2 | 6.30 ± 0.03 | 14/26 | 20 ± 2.4 | 426 ± 69 |
| P | >.9999 | .84 | .81 | .06 | |||
| MRDS | 15/5 | 46.2 ± 3.7 | 39.7 ± 2.8 | 6.28 ± 0.03 | 7/13 | 19 ± 3.4 | 513 ± 106 |
| Non-MRDS | 16/4 | 49.4 ± 3.8 | 44.9 ± 3.4 | 6.32 ± 0.05 | 7/13 | 20 ± 3.5 | 338 ± 86 |
| F2,57 = 0.21 | F2,57 = 0.66 | F2,57 = 2.07 | |||||
| P | .91 | .97 | .52 | .14 | >.9999 | .93 | .21 |
Abbreviations: Cpz, chlorpromazine equivalent dose; DOI, duration of illness; F, female; FRADD, final recorded antipsychotic drug dose; M, male; MRDS, muscarinic receptor deficit schizophrenia; non-MRDS, schizophrenia other than MRDS; PMI, postmortem interval; Sui, completed suicide.
Values are mean ± SEM or ratio.